Document Detail

Xanthine oxidase inhibitor in Duchenne muscular dystrophy.
MedLine Citation:
PMID:  6896406     Owner:  NLM     Status:  MEDLINE    
The treatment with xanthine oxidase inhibitor, allopurinol, was evaluated in 17 patients with Duchenne muscular dystrophy (aged 2 years 9 months to 13 years 9 months) using the double blind technique. The total observed period was 27 months. The results of 100-point scale of graded functional abilities revealed that an improvement, unchange and progression of dysfunction were found in 2, 2 and 6 patients, respectively, in allopurinol group and in 0, 2 and 5 patients, respectively in placebo group. The patients' age and stage of the disease seemed to be related to the effectiveness or allopurinol treatment.
H Tamari; Y Ohtani; A Higashi; S Miyoshino; I Matsuda
Related Documents :
1641586 - Long-term treatment with 300 mg ranitidine once daily after dilatation of peptic oesoph...
14770026 - Coinfection with giardia lamblia and clostridium difficile after use of ranitidine.
22327156 - Audit of stroke thrombolysis in wellington, new zealand: disparity between in-hours and...
6601256 - Sulfisoxazole chemoprophylaxis for frequent otitis media.
24344856 - Endovascular evaluation and treatment of intrahepatic portosystemic shunts in dogs: 100...
1396826 - Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Brain & development     Volume:  4     ISSN:  0387-7604     ISO Abbreviation:  Brain Dev.     Publication Date:  1982  
Date Detail:
Created Date:  1982-08-26     Completed Date:  1982-08-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7909235     Medline TA:  Brain Dev     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  137-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Triphosphate / metabolism
Allopurinol / therapeutic use*
Aspartate Aminotransferases / blood
Child, Preschool
Creatine Kinase / blood
Double-Blind Method
Muscles / metabolism
Muscular Dystrophies / drug therapy*,  enzymology
Xanthine Oxidase / antagonists & inhibitors*
Reg. No./Substance:
315-30-0/Allopurinol; 56-65-5/Adenosine Triphosphate; EC Oxidase; EC Aminotransferases; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of liquid meals on duodenogastric reflux in humans.
Next Document:  Anthelmintic efficacy of ivermectin given intramuscularly in horses.